Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

This trial is testing whether adding two immunotherapy drugs (IBI110 and sintilimab) to standard induction chemotherapy before surgery can improve outcomes for people with resectable, locally advanced head and neck squamous cell carcinoma. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with locally advanced squamous cell carcinoma of the head and neck (including the oropharynx, oral cavity, larynx, or hypopharynx) that can be surgically removed - Your cancer is Stage III to IVB - You have at least one measurable tumor lesion - You are in good physical condition (ECOG 0–1) - Your expected survival is more than 3 months **You may NOT be eligible if...** - Your cancer has already spread to distant organs - You have previously received treatment for this cancer - You have serious autoimmune disease or active infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.